Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Diabetes Publish Ahead of Print published online ahead of print April 28, 2008
DOI: 10.2337/db08-0176

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rodríguez-Calvo, R.
Right arrow Articles by Vázquez-Carrera, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodríguez-Calvo, R.
Right arrow Articles by Vázquez-Carrera, M.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

Activation of Peroxisome Proliferator-Activated Receptor β/{delta} (PPARβ/{delta}) Inhibits LPS-induced Cytokine Production in Adipocytes by Lowering NF-{kappa}B Activity via ERK1/2

Ricardo Rodríguez-Calvo1, Lucía Serrano1, Teresa Coll1, Norman Moullan2, Rosa M. Sánchez1, Manuel Merlos1, Xavier Palomer1, Juan C. Laguna1, Liliane Michalik2, Walter Wahli2, and Manuel Vázquez-Carrera1

1Pharmacology Unit, Department of Pharmacology and Therapeutic Chemistry, Faculty of Pharmacy, University of Barcelona, IBUB (Institut de Biomedicina de la UB), and CIBERDEM-Instituto de Salud Carlos III, Diagonal 643, E-08028 Barcelona, Spain and
2Center for Integrative Genomics, National Research Center Frontiers in Genetics, University of Lausanne, CH-1015 Lausanne, Switzerland

Objective: Chronic activation of the nuclear factor (NF)-{kappa}B in white adipose tissue leads to increased production of pro-inflammatory cytokines, which are involved in the development of insulin resistance. It is presently unknown whether Peroxisome Proliferator-Activated Receptor (PPAR)β/{delta} activation prevents inflammation in adipocytes.

Research Design and Methods and Results: Firstly, we examined whether the PPARβ/{delta} agonist GW501516 prevents LPS-induced cytokine production in differentiated 3T3-L1 adipocytes. Treatment with GW501516 blocked LPS-induced IL-6 expression and secretion by adipocytes and the subsequent activation of the STAT3-SOCS3 pathway. This effect was associated with the capacity of GW501516 to impede LPS-induced NF-{kappa}B activation. Secondly, in in vivo studies, white adipose tissue from Zucker Diabetic Fatty (ZDF) rats, compared to that of lean rats, showed reduced PPARβ/{delta} expression and PPAR DNA-binding activity, which was accompanied by enhanced IL-6 expression and NF-{kappa}B DNA-binding activity. Furthermore, IL-6 expression and NF-{kappa}B DNA-binding activity was higher in white adipose tissue from PPARβ/{delta}-null mice than in wild-type mice. Since mitogen-activated protein kinase (MAPK)–extracellular signal–related kinase (ERK)1/2 (MEK1/2) is involved in LPS-induced NF-{kappa}B activation in adipocytes, we explored whether PPARβ/{delta} prevented NF-{kappa}B activation by inhibiting this pathway. Interestingly, GW501516 prevented ERK1/2-phosphorylation by LPS. Further, white adipose tissue from animal showing constitutively increased NF-{kappa}B activity, such as ZDF rats and PPARβ/{delta}-null mice, also showed enhanced phospho-ERK1/2 levels.

Conclusions: These findings indicate that activation of PPARβ/{delta} inhibits enhanced cytokine production in adipocytes by preventing NF-{kappa}B activation via ERK1/2, an effect that may contribute to prevent insulin resistance.


Correspondence: mvazquezcarrera{at}ub.edu


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.